Date published: 2025-10-15

1-800-457-3801

SCBT Portrait Logo
Seach Input

C6orf62 Inhibitors

Chemical inhibitors of C6orf62 can exert their inhibitory effects through various biochemical pathways. Wortmannin and LY294002 are two such inhibitors that target phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, these chemicals disrupt downstream signaling pathways that are crucial for numerous cellular functions. As a result, C6orf62, which may rely on PI3K signaling for its activity, is functionally inhibited. Rapamycin operates through a different mechanism, targeting the mTOR pathway, which is central to cell growth and proliferation. The inhibition of mTOR can lead to a suppression of cellular activities that require C6orf62, thereby hindering its function. MEK inhibitors, such as PD98059 and U0126, obstruct the MAPK/ERK pathway, which is another fundamental signaling route that C6orf62 could utilize. By preventing the activation of ERK, these inhibitors may impede any functions of C6orf62 that are controlled via this pathway.

Further, SB203580 and SP600125 selectively inhibit p38 MAP kinase and c-Jun N-terminal kinase (JNK), respectively, affecting the stress response pathways that C6orf62 may be a part of. Y-27632, a Rho-associated protein kinase (ROCK) inhibitor, can alter cellular processes like motility and cytoskeletal organization, which, if connected with C6orf62, would result in functional inhibition. PD173074, an inhibitor of fibroblast growth factor receptors (FGFRs), could suppress C6orf62 function if it is involved in FGFR-mediated signaling. ALLN, which inhibits calpain and the proteasome, may lead to the accumulation of regulatory proteins that suppress C6orf62 function. Bisindolylmaleimide I disrupts protein kinase C (PKC) activity, which can inhibit C6orf62 if it is linked to pathways that involve PKC. Lastly, ZM 447439 inhibits Aurora kinases, which have a role in cell cycle regulation, and if C6orf62 is involved in these processes, its functional activity would be inhibited. Each of these chemicals interrupts specific pathways or cellular processes that are essential for the proper functioning of C6orf62, thus leading to its inhibition.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Wortmannin inhibits phosphoinositide 3-kinases (PI3K), which could lead to the inhibition of downstream signaling pathways that C6orf62 may be involved in, resulting in the functional inhibition of C6orf62.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 is another PI3K inhibitor that would disrupt PI3K/Akt signaling, thereby inhibiting any functions of C6orf62 that rely on this pathway for activation or stabilization.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin inhibits the mTOR pathway, which is involved in cell growth and proliferation. Inhibition of mTOR can suppress any cellular processes that require C6orf62 activity within those pathways.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

PD98059 inhibits MEK1, which intervenes in the MAPK/ERK pathway. Disruption of this pathway can lead to the inhibition of C6orf62 if it is functionally connected to the MAPK/ERK signaling.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

U0126, also a MEK inhibitor, would prevent the activation of ERK, potentially leading to the inhibition of C6orf62 activities that are regulated via the MAPK/ERK pathway.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

SB203580 selectively inhibits p38 MAP kinase, which might be involved in stress response pathways that C6orf62 is a part of, resulting in its functional inhibition.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), leading to the inhibition of stress-activated MAPK pathways, potentially inhibiting C6orf62 if it is regulated by these pathways.

Y-27632, free base

146986-50-7sc-3536
sc-3536A
5 mg
50 mg
$182.00
$693.00
88
(1)

Y-27632 inhibits the Rho-associated protein kinase (ROCK), which could inhibit C6orf62 by altering cellular processes like motility and cytoskeletal organization that C6orf62 may be involved in.

PD173074

219580-11-7sc-202610
sc-202610A
sc-202610B
1 mg
5 mg
50 mg
$46.00
$140.00
$680.00
16
(1)

PD173074 inhibits fibroblast growth factor receptors (FGFRs) and could inhibit C6orf62 function if C6orf62 is part of the FGFR-mediated signaling pathways.

Bisindolylmaleimide I (GF 109203X)

133052-90-1sc-24003A
sc-24003
1 mg
5 mg
$103.00
$237.00
36
(1)

Bisindolylmaleimide I inhibits protein kinase C (PKC), which could lead to the inhibition of C6orf62 if it is associated with pathways involving PKC activity.